Traws Pharma, Inc.
TRAW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001130598
No open-market purchases or sales by Traws Pharma, Inc. insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $5.19M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Traws Pharma, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 19 | 18 | −1 |
| Shares | 1.26M | 1.30M | +41.1K (+3.3%) |
| Value | $1.87M | $2.41M | +$543.3K (+29.1%) |
New holders (3)
Institutions that held Traws Pharma, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HRT Financial LP | 12,573 | $23.0K | 0.00% |
| XTX Topco Ltd | 10,708 | $19.8K | 0.00% |
| Assetmark, Inc | 2 | $4 | 0.00% |
Sold out (4)
Institutions that held Traws Pharma, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Alyeska Investment Group, L.P. | 52,630 | $77.9K |
| Two Sigma Securities, LLC | 17,169 | $25.4K |
| Tower Research Capital LLC (TRC) | 706 | $1.04K |
| Raymond James Financial Inc | 102 | $151 |